Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · IEX Real-Time Price · USD
177.93
+0.73 (0.41%)
At close: Mar 28, 2024, 4:00 PM
182.15
+4.22 (2.37%)
After-hours: Mar 28, 2024, 7:15 PM EDT
Krystal Biotech Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 159.64, with a low estimate of 139 and a high estimate of 195. The average target predicts a decrease of -10.28% from the current stock price of 177.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 27, 2024.
Analyst Ratings
The average analyst rating for KRYS stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 8 | 9 | 9 | 9 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citigroup | Citigroup | Strong Buy Maintains $160 → $195 | Strong Buy | Maintains | $160 → $195 | +9.59% | Feb 27, 2024 |
Guggenheim | Guggenheim | Strong Buy Maintains $130 → $175 | Strong Buy | Maintains | $130 → $175 | -1.65% | Feb 27, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $160 → $180 | Buy | Maintains | $160 → $180 | +1.16% | Dec 13, 2023 |
Goldman Sachs | Goldman Sachs | Strong Buy Initiates $160 | Strong Buy | Initiates | $160 | -10.08% | Nov 20, 2023 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $160 | Buy | Reiterates | $160 | -10.08% | Nov 7, 2023 |
Financial Forecast
Revenue This Year
249.83M
from 50.70M
Increased by 392.77%
Revenue Next Year
424.64M
from 249.83M
Increased by 69.97%
EPS This Year
1.33
from 0.39
Increased by 241.83%
EPS Next Year
4.11
from 1.33
Increased by 208.23%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 331.2M | 603.8M | 811.7M | 826.6M | 967.1M |
Avg | 249.8M | 424.6M | 617.7M | 639.2M | 792.9M |
Low | 172.3M | 246.0M | 472.5M | 512.5M | 595.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 553.2% | 141.7% | 91.1% | 33.8% | 51.3% |
Avg | 392.8% | 70.0% | 45.5% | 3.5% | 24.0% |
Low | 239.8% | -1.5% | 11.3% | -17.0% | -6.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 4.03 | 8.16 | 13.90 | 12.78 | 14.86 |
Avg | 1.33 | 4.11 | 8.71 | 9.07 | 13.23 |
Low | -1.17 | 0.33 | 2.98 | 3.76 | 11.56 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 933.8% | 512.0% | 238.3% | 46.8% | 63.8% |
Avg | 241.8% | 208.2% | 111.9% | 4.2% | 45.9% |
Low | - | -75.0% | -27.5% | -56.8% | 27.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.